Reducing primary melanoma mortality

Borden, Ernest C.

doi:10.1007/s11912-000-0020-1

Cited by 3 publications

(5 citation statements)

References 16 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, IFN-␥ has been used clinically in other disease states. [24][25][26] The present study indicates that IFN-␥ treatment results in a profound reduction in mature and primitive hematopoietic populations in Fancc Ϫ/Ϫ mice compared with WT mice. Importantly, this reduction in hematopoietic populations was sufficient to allow the engraftment and multilineage proliferation of exogenous repopulating stem cells.…”

Section: Discussionsupporting

confidence: 52%

Continuous in vivo infusion of interferon-gamma (IFN-γ) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice

Yang

Yuan

et al. 2004

Blood

View full text Add to dashboard Cite

Fanconi anemia (FA) is characterized by bone marrow (BM) failure and cancer susceptibility. Identification of the cDNAs of many FA complementation types allows the potential of using gene transfer technology to introduce functional cD-NAs as transgenes into autologous stem cells and provide a cure for the BM failure in FA patients. Previous studies in FA murine models and in a phase 1 clinical trial suggest that myelopreparation is required for significant engraftment of exog-enous, genetically corrected stem cells. Since myeloid progenitors from Fancc / mice and human Fanconi anemia group C protein (FANCC) patients have increased apoptosis in response to interferon (IFN-) in vitro, we hypothesized that IFN-may be useful as a nongenotoxic, myelo-preparative conditioning agent. To test this hypothesis, IFN-was administered as a continuous infusion to Fancc / and wild-type (WT) mice for 1 week. Primitive and mature myeloid lineages were preferentially reduced in IFN-treated Fancc / mice. Further, IFN-conditioning of Fancc / recipients was sufficient as a myelopreparative regimen to allow consistent engraftment of isogenic WT repopu-lating stem cells. Collectively, these data demonstrate that Fancc / hematopoietic cell populations have increased hypersen-sitivity to IFN-in vivo and that IFN-conditioning may be useful as a nongeno-toxic strategy for myelopreparation in this

show abstract

Section: Discussionsupporting

confidence: 52%

Continuous in vivo infusion of interferon-gamma (IFN-γ) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc-/- mice

Yang

Yuan

et al. 2004

Blood

View full text Add to dashboard Cite

show abstract

“…Interestingly, the observation that SSG as a single agent at a nontoxic dose had activity superior to that of IFN-␣ against WM9 tumors provides the first evidence suggesting that SSG monotherapy might be beneficial in cancer treatment. In addition, the finding that SSG interacted synergistically with IFN-␤ against WM9 melanoma cells in culture indicates that SSG might be of value in IFN-␤ therapies which are currently used in the treatment of a number of diseases, including cancer (e.g., melanoma) (29) and multiple sclerosis (35). Moreover, the synergistic anticancer effects of the SSG/IFN combination (Figs.…”

Section: Discussionmentioning

confidence: 93%

“…IFN-␣ induces ϳ15% clinical response in patients with melanoma (29). Drugs that augments IFN signaling to overcome IFN resistance might therefore improve response rates.…”

Section: Ssg Interacts Synergistically With Ifn-␣ and Ifn-␤ Against Wmentioning

confidence: 99%

Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs

Yi¹,

Pathak²,

Lindner³

et al. 2002

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Cancer cell resistance limits the efficacy of IFNs. In this study, we show that sodium stibogluconate (SSG) and IFN-α synergized to overcome IFN-α resistance in various human cancer cell lines in culture and eradicated IFN-α-refractory WM9 human melanoma tumors in nude mice with no obvious toxicity. SSG enhanced IFN-α-induced Stat1 tyrosine phosphorylation, inactivated intracellular SHP-1 and SHP-2 that negatively regulate IFN signaling, and induced cellular protein tyrosine phosphorylation in cancer cell lines. These effects are consistent with inactivation of phosphatases as the basis of SSG anticancer activity. Characterization of SSG by chromatography revealed that only selective compounds in SSG were effective protein tyrosine phosphatase inhibitors. These observations suggest the potential of SSG as a clinically usable protein tyrosine phosphatase inhibitor in cancer treatment and provide insights for developing phosphatase-targeted therapeutics.

show abstract

“…This responsiveness might be intrinsic for individual patients and related to the favorable treatment outcome of the patients in our study. Cytokine therapy using IL-2 or IFN-α induces durable regression of melanoma (Borden 2000) and renal cancer (McDermott and Atkins 2006) in only small patient populations. Identifi cation of patients likely to have positive responses prior to or at the early stages of treatment may improve the value and benefi t of cytokine therapy.…”

Section: Induction Of Human Peripheral Ifn-+ T Cells By Ssg/il-2 457mentioning

confidence: 99%

“…Among the PTPases, SHP-1 is a pivotal negative regulator of cytokine signaling and immune cell activation (Zhang and others 1999;Tsui and others 2006) and might be targeted by small chemical inhibitors to augment anticancer effi cacy of cytokine therapy and immunotherapy. Cytokine therapy of interleukin-2 (IL-2) or interferon (IFN)-α is standard of care for patients with advanced melanoma, inducing modest response rates (10-20%) (Borden 2000(Borden , 2005. Combination of the cytokines with an inhibitor of negative regulatory PTPases would be expected to enhance cytokine signaling and might lead to increased response rates.…”

Section: Introductionmentioning

confidence: 99%